Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 9/20 | 0.34 |
| ▸ | CA2 | P00918 | 9/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11367249 | 0.93 | BLM (0.47) | BLMPMP22HSD17B10ALDH1A1TSHR | |
| Malonic Acid SCHEMBL3706228 | 0.90 | BLM (0.55) | BLMPMP22HSD17B10ALDH1A1CA1 | |
| SCHEMBL5067890 | 0.88 | ALDH1A1 (0.50) | BLMPMP22HSD17B10ALDH1A1TSHR | |
| SCHEMBL11367338 | 0.87 | TSHR (0.42) | BLMPMP22HSD17B10ALDH1A1TSHR | |
| SCHEMBL6322193 | 0.85 | BLM (0.44) | BLMPMP22HSD17B10ALDH1A1TSHR | |
| Hexanoate SCHEMBL28978866 | 0.84 | AKR1B1 (0.52) | BLMPMP22HSD17B10ALDH1A1TSHR | |
| Dodecanoate SCHEMBL28979170 | 0.83 | GPR84 (0.53) | BLMHSD17B10ALDH1A1TSHRKDM5A | |
| Octanoic Acid SCHEMBL28979171 | 0.83 | GPR84 (0.53) | BLMHSD17B10ALDH1A1TSHRKDM5A | |
| SCHEMBL29415364 | 0.83 | TSHR (0.41) | BLMPMP22HSD17B10ALDH1A1TSHR | |
| SCHEMBL11370676 | 0.83 | TSHR (0.39) | BLMPMP22HSD17B10ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222449-B2 | Metal oxide-chelating ligands | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2012-07-17 | — | — | US | disclosed |
| US-20110137079-A1 | METAL OXIDE-CHELATING LIGANDS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110137079-A1 | METAL OXIDE-CHELATING LIGANDS | SOD1, SLC39A11, AP2S1 | BLM 2832/4885PMP22 3451/4885HSD17B10 4761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.